Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 14Thoracic 7Head & Neck 5Genitourinary 5Breast 4Gastrointestinal 3Other solid neoplasm 1Gynecologic 1

Conditions

Solid Tumors 2Solid Tumor, Adult 2Advanced Solid Tumors 2Advanced Solid Tumor 2Advanced Refractory Solid Tumors 2Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Mesothelioma, Malignant 1Melanoma 1MSI-H Advanced Colorectal Cancer 1Immune-related Adverse Event 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Malignant Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

pembrolizumab 12Nivolumab 6atezolizumab 3Ipilimumab 3tislelizumab 2spartalizumab 2durvalumab 2avelumab 2Etoposide 2ruxolitinib 1poly ICLC 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1entinostat 1cemiplimab 1budigalimab 1bemcentinib 1Thrombopoietin 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Levoleucovorin 1Leucovorin 1LY2940680 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Immune Checkpoint Inhibitors × Other solid neoplasm × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡